These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32804484)

  • 1. Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo.
    Tao Z; Liu Y; Yang H; Feng Y; Li H; Shi Q; Li S; Cheng J; Lu X
    Biomacromolecules; 2020 Oct; 21(10):4017-4029. PubMed ID: 32804484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Delivery to Tumor-associated Pericytes via an Affibody with High Affinity for PDGFRβ Enhances the
    Tao Z; Yang H; Shi Q; Fan Q; Wan L; Lu X
    Theranostics; 2017; 7(8):2261-2276. PubMed ID: 28740549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors.
    Jia D; Wang F; Lu Y; Hu P; Wang R; Li G; Liu R; Li J; Liu H; Fan Q; Yuan F
    Int J Pharm; 2022 May; 620():121746. PubMed ID: 35427745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein.
    Yang X; Xia X; Xia XX; Sun Z; Yan D
    Mol Pharm; 2021 Oct; 18(10):3854-3861. PubMed ID: 34543035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis.
    Li R; Li Z; Feng Y; Yang H; Shi Q; Tao Z; Cheng J; Lu X
    Apoptosis; 2020 Feb; 25(1-2):105-119. PubMed ID: 31894448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer.
    Shi Q; Tao Z; Yang H; Fan Q; Wei D; Wan L; Lu X
    Drug Deliv; 2017 Nov; 24(1):1818-1830. PubMed ID: 29182023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity.
    Yang H; Li H; Yang F; Tao Z; Shi Q; She T; Feng Y; Li Z; Chen J; Zhong Y; Su T; Zeng W; Zhang Y; Wang S; Li L; Long T; Long D; Cheng J; Zhu H; Lu X
    Biomaterials; 2023 Apr; 295():121994. PubMed ID: 36775789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
    Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
    Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel tumor-homing TRAIL variant eradicates tumor xenografts of refractory colorectal cancer cells in combination with tumor cell-targeted photodynamic therapy.
    Li Z; She T; Yang H; Su T; Shi Q; Tao Z; Feng Y; Yang F; Cheng J; Lu X
    Drug Deliv; 2022 Dec; 29(1):1698-1711. PubMed ID: 35635308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect.
    She T; Yang F; Chen S; Yang H; Tao Z; Xing H; Chen J; Chang H; Lu H; Su T; Jin Y; Zhong Y; Cheng J; Zhu H; Lu X
    J Control Release; 2023 Sep; 361():856-870. PubMed ID: 37516318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of pericytes by a fusion protein comprising of a PDGFRβ-antagonistic affibody and TNFα induces tumor vessel normalization and improves chemotherapy.
    Fan Q; Tao Z; Yang H; Shi Q; Wang H; Jia D; Wan L; Zhang J; Cheng J; Lu X
    J Control Release; 2019 May; 302():63-78. PubMed ID: 30930215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Versatile Platform to Generate Prodrugs with Rapid and Precise Albumin Hitchhiking and High Cargo Loading for Tumor-Targeted Chemotherapy.
    Li J; Xing H; Chen J; Lu H; Tao Z; Tao Y; Sun Y; Su T; Li X; Chang H; Chen S; Chen Z; Yang H; Cheng J; Zhu H; Lu X
    Small; 2024 Mar; 20(13):e2304253. PubMed ID: 37963821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Prokaryotic Expression and Purification of Bioactive Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.
    Do BH; Nguyen MT; Song JA; Park S; Yoo J; Jang J; Lee S; So S; Yoon Y; Kim I; Lee K; Jang YJ; Choe H
    J Microbiol Biotechnol; 2017 Dec; 27(12):2156-2164. PubMed ID: 29032646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.
    Lavazza C; Carlo-Stella C; Giacomini A; Cleris L; Righi M; Sia D; Di Nicola M; Magni M; Longoni P; Milanesi M; Francolini M; Gloghini A; Carbone A; Formelli F; Gianni AM
    Blood; 2010 Mar; 115(11):2231-40. PubMed ID: 20075160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.